Gamco Investors, Inc. Et Al

recently disclosed that they own a 9.2% stake in BioScrip, Inc. (NASDAQ:BIOS) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission on Friday, August 11th. The investor owns 11,721,893 shares of the stock worth approximately $37,978,933. The reporting parties listed on the disclosure included Gabelli Funds, LLC ID No 134044523, GAMCO Asset Management Inc ID No 134044521, Teton Advisors, Inc ID No 134008049, Gabelli & Company Investment Advisers, Inc ID No 133379374, GGCP, Inc ID No 133056041, GAMCO Investors, Inc ID No 134007862, Associated Capital Group, Inc ID No 473965991 and Mario J Gabelli. The filing is available through EDGAR at this link.

Gamco Investors, Inc. Et Al

provided the following explanation of their ownership:

Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Warning: file_get_contents(https://whalewisdom.com
11,721,893
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Several other large investors also recently made changes to their positions in BIOS. Goldman Sachs Group Inc. boosted its position in shares of BioScrip by 65.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock worth $109,000 after buying an additional 25,500 shares during the period. American International Group Inc. boosted its position in shares of BioScrip by 73.8% in the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock worth $115,000 after buying an additional 28,787 shares during the period. Captrust Financial Advisors acquired a new position in shares of BioScrip during the second quarter worth about $123,000. Alambic Investment Management L.P. acquired a new position in shares of BioScrip during the first quarter worth about $160,000. Finally, Citadel Advisors LLC acquired a new position in shares of BioScrip during the first quarter worth about $161,000. 91.16% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BioScrip, Inc. (NASDAQ:BIOS) traded up 5.19% on Friday, reaching $3.24. 2,426,194 shares of the company were exchanged. The company’s 50-day moving average is $2.84 and its 200-day moving average is $2.03. BioScrip, Inc. has a 52 week low of $0.98 and a 52 week high of $3.43. The company’s market capitalization is $413.02 million.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $218.11 million for the quarter, compared to analyst estimates of $220.05 million. During the same quarter in the prior year, the company earned ($0.14) EPS. The business’s quarterly revenue was down 6.2% on a year-over-year basis. On average, equities analysts expect that BioScrip, Inc. will post ($0.55) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/bioscrip-inc-bios-stake-maintained-by-gamco-investors-inc-et-al/1476189.html.

BIOS has been the subject of a number of recent research reports. Barrington Research lifted their price target on shares of BioScrip to $3.50 and gave the company an “outperform” rating in a research report on Monday, June 26th. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Jefferies Group LLC reissued a “buy” rating and set a $4.00 price target (up from $3.00) on shares of BioScrip in a research report on Thursday. ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Finally, SunTrust Banks, Inc. raised shares of BioScrip from a “hold” rating to a “buy” rating and lifted their price target for the company from $3.25 to $3.75 in a research report on Thursday. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $3.75.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Want to see what other hedge funds are holding BIOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioScrip, Inc. (NASDAQ:BIOS).

Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.